ASH 2018 | Personalized AML therapy with John Byrd: the beat AML trial and more
John Byrd
• 17 Jan 2019
John Byrd, MD, of Ohio State University, Columbus, OH, describes the difficulty in assigning therapy to different acute myeloid leukemia (AML) patients. He explains how the Beat AML study is allowing precision medicine to be applied to AML. Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Byrd goes on to discuss how research, such as the work of Dr Stein on the IDH2 inhibitor enasidenib, is helping to treat AML and avoid the use of chemotherapy.
